Voyager Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2014
Net Income	132.33	-46.41	-71.2	36.74	-43.6	Upgrade
Depreciation & Amortization	4.44	6.19	5.17	3.82	2.77	Upgrade
Share-Based Compensation	11.15	9.34	11.32	14.93	15.64	Upgrade
Other Operating Activities	-70.01	18.36	1.18	-152.21	73.86	Upgrade
Operating Cash Flow	77.92	-12.51	-53.53	-96.72	48.67	Upgrade
Capital Expenditures	-3.26	-2.49	-1.61	-12.1	-7.55	Upgrade
Change in Investments	-138.39	-4.85	67.52	125.09	-82.93	Upgrade
Investing Cash Flow	-141.64	-7.34	65.91	113	-90.48	Upgrade
Share Issuance / Repurchase	33.65	1.11	0.61	3.16	80.99	Upgrade
Financing Cash Flow	33.65	1.11	0.61	3.16	80.99	Upgrade
Net Cash Flow	-30.08	-18.74	12.99	19.44	39.18	Upgrade
Free Cash Flow	74.66	-15	-55.13	-108.81	41.12	Upgrade
Free Cash Flow Margin	29.86%	-36.67%	-147.36%	-63.59%	39.39%	Upgrade
Free Cash Flow Per Share	1.74	-0.39	-1.46	-2.93	1.15	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).